Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Minerva Neurosciences Inc(NERV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NERV
09/25/2026: NERV (1-star) is currently NOT-A-BUY. Pass it for now.
Minerva Neurosciences is a clinical-stage biotechnology company focused on developing proprietary therapies for central nervous system disorders, primarily schizophrenia. The company's main strength lies in its specialized pipeline, particularly its investigative candidate Roluperidone. While the potential for a novel treatment for negative symptoms represents a significant growth opportunity, the firm faces immense execution and regulatory risks, highlighted by recent FDA setbacks. With no current commercial revenue and high development costs, the stock is a speculative, high-risk investment better suited for those comfortable with biotechnology volatility. Investors should closely monitor regulatory communications and the company's capital preservation efforts as it navigates a challenging path toward potential approval.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company lacks revenue growth, making it a speculative clinical-stage play rather than a traditional growth stock. |
| Momentum investor | Weak fit | Momentum is conditional on positive news flow and price upturns, which are currently absent. |
| Value investor | Weak fit | Traditional value metrics cannot be applied to a company without earnings or product revenue. |
| Dividend investor | Weak fit | Minerva does not pay a dividend and is unlikely to do so in the near future. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology carries high inherent investment risk and volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | High | Valuation is speculative and based entirely on future development success. |
| Competition risk (Pharma/CNS) | High | Large incumbents with massive R&D budgets dominate the CNS market. |
| Business quality | Low | The company lacks a proven commercial product or stable revenue stream. |
| Dividend income | Low / none | No income potential exists for investors. |
| Execution risk | High | Success depends on complex clinical and regulatory milestones. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -11.8% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 162.34M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 238.8K shares | Beta -0.1 | 52 Weeks Range 2.06 - 8.80 | Updated Date 09/27/2026 |
52 Weeks Range 2.06 - 8.80 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -36.12 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CNS Therapeutics | Clinical-stage development of drugs like Roluperidone. | The company is not currently profitable and relies on research to create future products. |
Valuation
Trailing PE - | Forward PE 11.21 | Enterprise Value 91.37M | Price to Sales(TTM) 1.87 |
Enterprise Value 91.37M | Price to Sales(TTM) 1.87 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 47.75M | Shares Floating 34.30M |
Shares Outstanding 47.75M | Shares Floating 34.30M | ||
Percent Insiders 3.26 | Percent Institutions 93.31 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Minerva Neurosciences Inc
Exchange NASDAQ | Headquarters Burlington, MA, United States | ||
IPO Launch date 2014-07-01 | Executive Chairman, CEO & Member of Scientific Advisory Board Dr. Remy Luthringer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.